Ascentage Pharma Group International (AAPG)vsInsmed Inc (INSM)
AAPG
Ascentage Pharma Group International
$22.32
0.00%
HEALTHCARE · Cap: $1.79B
INSM
Insmed Inc
$139.14
-3.36%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 55% more annual revenue ($606.42M vs $390.60M). INSM leads profitability with a -210.5% profit margin vs -296.8%. INSM earns a higher WallStSmart Score of 39/100 (F).
AAPG
Avoid15
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 152.6% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 79.7x book value
ROE of -159.7% — below average capital efficiency
0.0% earnings growth
Trading at 40.3x book value
ROE of -249.3% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AAPG
AAPG has a balanced fundamental profile.
Bull Case : INSM
The strongest argument for INSM centers on Revenue Growth. Revenue growth of 152.6% demonstrates continued momentum. PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : AAPG
The primary concerns for AAPG are EPS Growth, Market Cap, Price/Book.
Bear Case : INSM
The primary concerns for INSM are EPS Growth, Price/Book, Return on Equity.
Key Dynamics to Monitor
AAPG profiles as a turnaround stock while INSM is a hypergrowth play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 152.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 15/100) and 152.6% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascentage Pharma Group International
HEALTHCARE · BIOTECHNOLOGY · USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?